CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results

0
46

In the release dated May 13, 2021, the “Program starts, cumulative” figure for the period ended March 31, 2021 in both the Key Business Metrics table and the following paragraph should read 54 instead of 52. The resulting percent change from the prior period (“Change %) in the table should read 15% instead of 11%.

The corrected release reads:

ABCELLERA REPORTS Q1 2021 BUSINESS RESULTS

  • Total revenue of $203 million, up from $5 million in Q1 2020

  • Total programs under contract of 119, up 63% year-over-year

  • EPS of $0.43 (basic) and $0.37 (diluted) compared to $0.01 loss per share in Q1 2020

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2021.

“Our partnership business continued to thrive in the first quarter of 2021, expanding our diversified program portfolio through collaborations with both new and existing partners,” said Carl…

Read more…